Lymphatics and Blood Pressure

Mattson, David L.

doi:10.1161/hypertensionaha.122.20166

Cited by 2 publications

(2 citation statements)

References 14 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…A study has shown that serum VEGF-C levels are decreased in patients with hypertension, lymph angiogenesis, and the protective function of the lymphatic system are impaired. In addition, it has been suggested that decreased VEGF-C decreases the density of the capillary network [ 21 , 37 ]. Low-grade inflammation in metabolic syndrome is another issue that should not be ignored.…”

Section: Discussionmentioning

confidence: 99%

A comparative evaluation of the efficacy of complete decongestive therapy in the treatment of unilateral breast cancer–related lymphedema with and without metabolic syndrome

Pirincci,

Mete,

Yasa

et al. 2024

Support Care Cancer

View full text Add to dashboard Cite

Aim This study aimed to investigate the effect of the presence of metabolic syndrome (MetS) on the limb volume and quality of life (QoL) of patients who underwent complex decongestive therapy (CDT) due to unilateral breast cancer-related lymphedema (BCRL). Methods Forty female patients with unilateral BCRL, of whom 20 had MetS (MetS group) and 20 did not have MetS (control group), were included in the study. The participants received CDT 5 days a week for 3 weeks. The participants’ limb volume (percentage of excess volume (PEV) and percentage reduction of excess volume (PREV) was determined using a tape measure, and their QoL was assessed using the Lymphedema Quality of Life questionnaire (LYMQoL) before and after treatment. Results After the treatment, the PEV and PREV values and LYMQoL-symptoms scores of the patients improved (p < 0.05); however, the LYMQoL-function, appearance/body image, mood/emotions, and overall QoL scores did not change in the MetS group (p > 0.05). In the control group, the PEV and PREV values and the LYMQoL-appearance/body image, mood/emotions, and overall QoL scores improved (p < 0.05), but the LYMQoL-symptoms and LYMQoL-function scores did not change (p > 0.05). There was a greater increase in the post-treatment PEV and PREV values of the control group compared to the MetS group (p < 0.001). Conclusion The study yielded that CDT was an effective treatment in BCRL with and without MetS; however, the improvement was greater in BCRL cases without MetS than in those with MetS. Therefore, the presence of MetS should be taken into account in the treatment of lymphedema in patients who develop BCRL. Trial registration ClinicalTrials.gov, identifier: NCT05426993. Registered 2022–06-16. https://clinicaltrials.gov/search?cond=NCT05426993

show abstract

Section: Discussionmentioning

confidence: 99%

A comparative evaluation of the efficacy of complete decongestive therapy in the treatment of unilateral breast cancer–related lymphedema with and without metabolic syndrome

Pirincci,

Mete,

Yasa

et al. 2024

Support Care Cancer

View full text Add to dashboard Cite

show abstract

“…[40][41][42] While there is exciting ongoing research on the contributions of the immune system to hypertension, most of these studies do not currently consider the bidirectional alliance between the microbiota and the host immune system. [43][44][45][46][47] One group of studies to consider this relationship demonstrates that dietary salt alters the microbiota, including reducing gut lactobacilli. 6,48 In this salt-sensitive model, these shifts in the microbiota were mechanistically linked to elevated host T helper 17 (Th17) cells and hypertension.…”

Section: Microbiota and The Immune Systemmentioning

confidence: 99%

Prospects for Leveraging the Microbiota as Medicine for Hypertension

Durgan,

Zubcevic,

Vijay-Kumar

et al. 2024

Hypertension

View full text Add to dashboard Cite

Lymphatics and Blood Pressure

Cited by 2 publications

References 14 publications

A comparative evaluation of the efficacy of complete decongestive therapy in the treatment of unilateral breast cancer–related lymphedema with and without metabolic syndrome

A comparative evaluation of the efficacy of complete decongestive therapy in the treatment of unilateral breast cancer–related lymphedema with and without metabolic syndrome

Prospects for Leveraging the Microbiota as Medicine for Hypertension

Contact Info

Product

Resources

About